Cytokinetics Announces Presentations at the Cure SMA 2017 Annual SMA Conference
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced presentations at the Cure SMA 2017 Annual SMA Conference from June 29 - July 2, 2017 in Orlando, FL. In an oral presentation on July 1, Stacy Rudnicki, M.D., Director, Clinical Research and Development at Cytokinetics will present data relating to patient baseline characteristics and the reasons for patient screen failure from the first cohort of the Phase 2 clinical trial of CK-2127107 in spinal muscular atrophy (SMA). Additionally, Dr. Rudnicki will participate in a panel discussion on SMA drugs in development on July 1. During a poster session on June 30, Eva Chin, Ph.D., Director, Pharmacology, Muscle Biology & Therapeutics at Cytokinetics will present preclinical data for CK-2127107 in mouse models of SMA. Oral Presentation Date: Saturday, July 1, 2017Location: Ballroom of America BSession: SMA Therapy DevelopmentTime: 10:00 AMTitle: Clinical Trial Updat
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics to Announce First Quarter Results on May 8, 2024GlobeNewswire
- Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressGlobeNewswire
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.MarketBeat
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $86.00 price target on the stock.MarketBeat
CYTK
Earnings
- 2/27/24 - Miss
CYTK
Sec Filings
- 4/15/24 - Form 4
- 4/9/24 - Form 4
- 4/9/24 - Form 144
- CYTK's page on the SEC website